₹375 levels for the last three months.The company announced that it is working on two covid-19 vaccines. While one is leading candidate showing safety in animal studies, initial human trials have only just begun.
These trials could take three months, may be even more. Besides, several critical phases in vaccine development remain. Hence, commercialisation may still be distant.But analysts see the development as a positive if the vaccine does make it to the market. “While there are several milestones before commercial launch, we believe a positive development on the covid-19 vaccine can re-rate the stock in the near term.